A clinical trial using benralizumab significantly reduced eosinophil counts but failed to ease symptoms, highlighting a gap in our understanding of the disease’s underlying mechanisms. A new study ...

Key opinion leaders interviewed by GlobalData consistently highlight the value of mechanism-specific targeting in eosinophilic ... highlights the effectiveness of biologics such as mepolizumab and ...

If further validated in Phase III trials, tezepelumab could secure a foothold as a biomarker-driven add-on therapy, potentially capturing market share from other biologics with overlapping mechanisms.

FASENRA® (benralizumab) injection for subcutaneous ... 8 Results are descriptive only. FASENRA’s mechanism of action leads to near-complete depletion of eosinophils. 8 The mechanism of action ...

(Image Credits: Pixabay) AstraZeneca’s Fasenra (benralizumab), with its highly ... With its innovative mechanism of action and established success in asthma, Fasenra could address critical ...

TUESDAY, Dec. 10, 2024 (HealthDay News) -- Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a ...

The same biological mechanism also underlies a third of all ... with asthma attacks almost every day. But the benralizumab injection he had in hospital helped stabilise his disease.

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). The FDA has approved an expanded indication of AstraZeneca’s benralizumab ...